Lipocine Earnings Estimate
| LPCN Stock | USD 8.52 0.29 3.29% |
Lipocine Earnings Estimation Breakdown
The calculation of Lipocine's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Lipocine is estimated to be -0.49125 with the future projection ranging from a low of -0.4925 to a high of -0.49. Please be aware that this consensus of annual earnings estimates for Lipocine is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.49 Lowest | Expected EPS | -0.49 Highest |
Lipocine Earnings Projection Consensus
Suppose the current estimates of Lipocine's value are higher than the current market price of the Lipocine stock. In this case, investors may conclude that Lipocine is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Lipocine's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 2 | 72.88% | -0.59 | -0.49125 | -1.02 |
Lipocine Earnings per Share Projection vs Actual
Actual Earning per Share of Lipocine refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Lipocine predict the company's earnings will be in the future. The higher the earnings per share of Lipocine, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Lipocine Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Lipocine, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Lipocine should always be considered in relation to other companies to make a more educated investment decision.Lipocine Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Lipocine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-06 | 2025-09-30 | -0.54 | -0.59 | -0.05 | 9 | ||
2025-08-05 | 2025-06-30 | -0.4 | -0.41 | -0.01 | 2 | ||
2025-05-07 | 2025-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2025-03-05 | 2024-12-31 | -0.4 | 0.33 | 0.73 | 182 | ||
2024-11-06 | 2024-09-30 | -0.48 | -0.41 | 0.07 | 14 | ||
2024-08-08 | 2024-06-30 | -0.78 | -0.57 | 0.21 | 26 | ||
2024-05-09 | 2024-03-31 | -0.68 | 0.66 | 1.34 | 197 | ||
2024-03-07 | 2023-12-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2023-11-08 | 2023-09-30 | -0.6 | -1.27 | -0.67 | 111 | ||
2023-08-10 | 2023-06-30 | -0.64 | -0.68 | -0.04 | 6 | ||
2023-05-11 | 2023-03-31 | -0.42 | -0.68 | -0.26 | 61 | ||
2023-03-10 | 2022-12-31 | -0.03 | -0.03 | 0.0 | 0 | ||
2022-11-09 | 2022-09-30 | -0.03 | -0.03 | 0.0 | 0 | ||
2022-08-08 | 2022-06-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2022-05-09 | 2022-03-31 | -0.02 | -0.04 | -0.02 | 100 | ||
2022-03-09 | 2021-12-31 | -0.01 | 0.15 | 0.16 | 1600 | ||
2021-11-10 | 2021-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2021-08-05 | 2021-06-30 | -0.05 | -0.03 | 0.02 | 40 | ||
2021-05-06 | 2021-03-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2021-03-11 | 2020-12-31 | -0.06 | -0.06 | 0.0 | 0 | ||
2020-11-10 | 2020-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2020-08-06 | 2020-06-30 | -0.07 | -0.13 | -0.06 | 85 | ||
2020-05-07 | 2020-03-31 | -0.08 | -0.14 | -0.06 | 75 | ||
2020-03-13 | 2019-12-31 | -0.15 | -0.1 | 0.05 | 33 | ||
2019-11-12 | 2019-09-30 | -0.16 | -0.12 | 0.04 | 25 | ||
2019-08-07 | 2019-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2019-05-08 | 2019-03-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2019-03-06 | 2018-12-31 | -0.12 | -0.15 | -0.03 | 25 | ||
2018-11-07 | 2018-09-30 | -0.24 | -0.12 | 0.12 | 50 | ||
2018-08-07 | 2018-06-30 | -0.25 | -0.15 | 0.1 | 40 | ||
2018-05-07 | 2018-03-31 | -0.21 | -0.13 | 0.08 | 38 | ||
2018-03-12 | 2017-12-31 | -0.23 | -0.25 | -0.02 | 8 | ||
2017-11-08 | 2017-09-30 | -0.21 | -0.22 | -0.01 | 4 | ||
2017-08-07 | 2017-06-30 | -0.3 | -0.31 | -0.01 | 3 | ||
2017-05-08 | 2017-03-31 | -0.3 | -0.26 | 0.04 | 13 | ||
2017-03-06 | 2016-12-31 | -0.28 | -0.16 | 0.12 | 42 | ||
2016-11-08 | 2016-09-30 | -0.29 | -0.18 | 0.11 | 37 | ||
2016-08-09 | 2016-06-30 | -0.37 | -0.32 | 0.05 | 13 | ||
2016-05-09 | 2016-03-31 | -0.32 | -0.38 | -0.06 | 18 | ||
2016-03-10 | 2015-12-31 | -0.29 | -0.25 | 0.04 | 13 | ||
2015-11-12 | 2015-09-30 | -0.25 | -0.35 | -0.1 | 40 | ||
2015-08-11 | 2015-06-30 | -0.2 | -0.26 | -0.06 | 30 | ||
2015-05-07 | 2015-03-31 | -0.25 | -0.23 | 0.02 | 8 | ||
2015-03-11 | 2014-12-31 | -0.27 | -0.32 | -0.05 | 18 | ||
2014-11-10 | 2014-09-30 | -0.55 | -0.32 | 0.23 | 41 | ||
2014-08-13 | 2014-06-30 | -0.42 | -0.55 | -0.13 | 30 | ||
2014-05-14 | 2014-03-31 | -0.41 | -0.41 | 0.0 | 0 | ||
2014-03-31 | 2013-12-31 | -0.27 | -0.3 | -0.03 | 11 |
About Lipocine Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Lipocine earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Lipocine estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Lipocine fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -179.8 M | -188.8 M | |
| Retained Earnings Total Equity | -155.4 M | -163.2 M | |
| Price Earnings Ratio | 2.8 K | 2.9 K | |
| Price Earnings To Growth Ratio | (35.86) | (34.06) |
Pair Trading with Lipocine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipocine Stock
| 0.72 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Lipocine Stock
| 0.9 | HPQ | HP Inc Aggressive Push | PairCorr |
| 0.62 | MSFT | Microsoft Sell-off Trend | PairCorr |
| 0.59 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.48 | VLCN | Volcon Inc Symbol Change | PairCorr |
| 0.37 | IBM | International Business | PairCorr |
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth 5.954 | Return On Assets | Return On Equity |
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.